James Hatton, QC, is a commercial solicitor with more than 30 years experience in assisting companies to exploit the value of their intellectual property assets. James is the partner responsible for the Technology Group at Farris LLP and is Repeatedly Recommended by Lexpert® in the fields of Technology Transactions and Biotechnology. Best Lawyers lists James in the practice areas of Intellectual Property Law and Biotechnology Law and named James as Vancouver’s “Biotechnology Law Lawyer of the Year” for 2013, 2017 and 2019. Transactions of note include acting for Cardiome in the Cardiome Merck alliance, one of the largest cardiovascular life sciences alliances in the world and the largest in the history of the Canadian life sciences industry. He also acted for United Therapeutics in the United Therapeutics Lilly alliance, the Licensing Executives Society’s Deal of Distinction award winner for the Healthcare Sector. James is a board director, including the board of BC Hydro, Powerex, BC Tech Association and The Forum for Women Entrepreneurs. He is an advisory board member for STEMCELL Technologies and a director and past Chair of LifeSciences BC. He is a former member of the National Research Council of Canada and a former member of the board of governors of Royal Roads University.
On August 18, 2015, Diversified Royalty Corp. (DIV) completed an offering of subscription receipts. The offering raised gross proceeds of approximately $115.0 million through the issuance of 42,595,000 subscription receipts, which included 1,854,000 subscription receipts issued as a result of the underwriters electing to exercise the over-allotment option in part. The offering was conducted by a syndicate of underwriters led by Cormark Securities Inc. and including GMP Securities L.P., CIBC World Markets Inc., PI Financial Corp., Beacon Securities Limited and Paradigm Capital Inc.